- Home
- GLPG vs CERT Comparison
GLPG vs CERT Comparison
Compare GLPG & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- CERT
- Stock Information
- Founded
- GLPG 1999
- CERT 2008
- Country
- GLPG Belgium
- CERT United States
- Employees
- GLPG N/A
- CERT N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- GLPG Health Care
- CERT Technology
- Exchange
- GLPG Nasdaq
- CERT Nasdaq
- Market Cap
- GLPG 1.8B
- CERT 1.9B
- IPO Year
- GLPG 2005
- CERT 2020
- Fundamental
- Price
- GLPG $29.92
- CERT $11.40
- Analyst Decision
- GLPG Sell
- CERT Buy
- Analyst Count
- GLPG 4
- CERT 7
- Target Price
- GLPG $25.33
- CERT $15.67
- AVG Volume (30 Days)
- GLPG 226.8K
- CERT 2.0M
- Earning Date
- GLPG 07-23-2025
- CERT 08-05-2025
- Dividend Yield
- GLPG N/A
- CERT N/A
- EPS Growth
- GLPG N/A
- CERT N/A
- EPS
- GLPG N/A
- CERT N/A
- Revenue
- GLPG $311,493,731.00
- CERT $394,498,000.00
- Revenue This Year
- GLPG $0.78
- CERT $11.57
- Revenue Next Year
- GLPG N/A
- CERT $8.93
- P/E Ratio
- GLPG N/A
- CERT N/A
- Revenue Growth
- GLPG 18.32
- CERT 9.37
- 52 Week Low
- GLPG $22.36
- CERT $8.64
- 52 Week High
- GLPG $31.23
- CERT $16.93
- Technical
- Relative Strength Index (RSI)
- GLPG 62.12
- CERT 51.98
- Support Level
- GLPG $28.21
- CERT $10.83
- Resistance Level
- GLPG $29.23
- CERT $11.98
- Average True Range (ATR)
- GLPG 0.53
- CERT 0.40
- MACD
- GLPG 0.09
- CERT 0.07
- Stochastic Oscillator
- GLPG 93.93
- CERT 70.25
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.